Tag Archives: Lara Marks

Upcoming UCL seminar May 3rd 4:30 pm by Dr Lara Marks: ‘History on-line: The case of monoclonal antibodies’

We are delighted to announce Dr Lara Marks’ upcoming seminar on May 3rd on ‘History on-line: The case of monoclonal antibodies’. When: Wednesday May 3rd 4.30pm Where: Darwin Building room B05, University College London Dr Lara Marks’ talk will tell the … Continue reading

Posted in History of Medicine | Tagged , | Leave a comment

Need for public engagement CRISPR/Cas9 Genome Editing debate – beyond embryo modification

Dr Silvia Camporesi and Dr Lara Marks comment for the Conversation on the recent application by researchers at Francis Crick institute to the Human Fertilisation and Embryology Authority to use CRISPR/Cas9 genome editing technologies to  human embryos: This is a controversial move, which would … Continue reading

Posted in Bioethics | Tagged , , | Leave a comment

The Summer Issue of the SSHM Newsletter is out!

We are pleased to announce the publication of the Summer 2015 newsletter of the Department of Social Science, Health and Medicine (SSHM) at King’s College London. Here are some highlights of the summer issue: What our students do after they graduate: featuring Rose Mortimer, … Continue reading

Posted in Bioethics | Tagged , , , , , , | Leave a comment

Feb 6th SSHM Dr Lara Marks spoke to BBC Radio 4 about Carl Djerassi

On February 6th Dr Lara Marks spoke to BBC Radio 4 about Carl Djerassi, the inventor of the contraceptive pill. You can listen to the interview here. Lara Marks is a trained historian of medicine, who has a long history … Continue reading

Posted in Bioeconomy, Bioethics, Health Policy, Public Policy | Tagged , , , , , | Leave a comment

FDA Approves Lemtrada for MS: Dr Lara Marks recounts the story of the drug in “The life story of a Biotechnology drug: Alemtuzumab”

On November 14 2014 the FDA announced the approval of Lemtrada (alemtuzumab) as a treatment for patients with relapsing forms of multiple sclerosis (MS) who have previously failed two other drugs. This decision marked the culmination of a long and … Continue reading

Posted in Health Policy, Neuroscience | Tagged , , , | Leave a comment